Robert W. Baird Issues Pessimistic Forecast for Cognex (NASDAQ:CGNX) Stock Price

Cognex (NASDAQ:CGNX) had its target price cut by Robert W. Baird from $78.00 to $70.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the scientific and technical instruments company’s stock. Robert W. Baird’s target price points to a potential upside of 18.70% from the company’s previous close.

CGNX has been the topic of a number of other research reports. Cantor Fitzgerald boosted their price target on Cognex from $76.00 to $84.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. UBS Group set a $75.00 target price on Cognex in a research note on Tuesday, May 26th. JPMorgan Chase & Co. raised Cognex from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $65.00 to $75.00 in a report on Tuesday, May 26th. Zacks Research upgraded Cognex from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 16th. Finally, Citigroup reaffirmed a “neutral” rating and set a $74.00 price target (up from $72.00) on shares of Cognex in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $75.50.

Cognex Price Performance

Shares of CGNX opened at $58.97 on Wednesday. The firm has a 50-day moving average of $62.50 and a 200-day moving average of $60.33. Cognex has a one year low of $34.60 and a one year high of $72.88. The company has a market cap of $9.92 billion, a PE ratio of 57.25 and a beta of 1.49.

Cognex (NASDAQ:CGNX) last issued its earnings results on Wednesday, August 5th. The scientific and technical instruments company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. Cognex had a net margin of 16.05% and a return on equity of 13.50%. The company had revenue of $291.26 million for the quarter, compared to analysts’ expectations of $292.10 million. During the same period in the prior year, the firm earned $0.25 EPS. Cognex’s quarterly revenue was up 16.9% compared to the same quarter last year. Cognex has set its FY 2026 guidance at 1.640-1.680 EPS and its Q3 2026 guidance at 0.500-0.540 EPS. Analysts expect that Cognex will post 1.68 earnings per share for the current year.

Institutional Trading of Cognex

A number of institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC increased its position in shares of Cognex by 124.5% in the fourth quarter. Intech Investment Management LLC now owns 98,451 shares of the scientific and technical instruments company’s stock worth $3,542,000 after purchasing an additional 54,600 shares during the period. One Capital Management LLC bought a new position in Cognex in the 4th quarter valued at about $1,945,000. Legal & General Group Plc raised its position in shares of Cognex by 11.1% in the 4th quarter. Legal & General Group Plc now owns 1,152,053 shares of the scientific and technical instruments company’s stock valued at $41,451,000 after buying an additional 114,652 shares in the last quarter. Robinhood Asset Management LLC bought a new stake in shares of Cognex during the 2nd quarter worth approximately $16,461,000. Finally, Hsbc Holdings PLC boosted its position in shares of Cognex by 210.3% during the 4th quarter. Hsbc Holdings PLC now owns 58,932 shares of the scientific and technical instruments company’s stock worth $2,127,000 after acquiring an additional 39,937 shares in the last quarter. Institutional investors own 88.12% of the company’s stock.

Trending Headlines about Cognex

Here are the key news stories impacting Cognex this week:

• Positive Sentiment: The acquisition adds RealSense’s 3D perception platform and is expected to expand Cognex’s addressable market, particularly in robotics applications requiring cameras and vision systems to identify, locate, and manipulate objects. Management characterized the transaction as supporting growth diversification. Cognex to Acquire RealSense, Expanding Machine Vision Leadership into High-Growth Robotic Perception Market
• Positive Sentiment: Needham initiated Cognex at Buy with an $80 price target, citing the RealSense transaction and an expanding robotic-perception opportunity. That target is meaningfully above the company’s recent trading range and signals potential upside if the acquisition accelerates growth. Cognex Initiated at Buy on RealSense Acquisition
• Neutral Sentiment: D.A. Davidson kept a Hold rating and its $65 target, viewing the deal valuation as broadly fair rather than immediately accretive. The split analyst reaction suggests investors are weighing RealSense’s strategic potential against the purchase price and the time needed to realize synergies. Cognex Maintained at Hold as RealSense Deal Seen Fairly Valued
• Negative Sentiment: The $500 million cash outlay creates execution, integration, and return-on-investment risks, while Cognex already trades at a relatively high valuation of roughly 57 times earnings. Investors may therefore demand evidence that RealSense can contribute meaningfully to revenue and earnings growth. Cognex To Buy RealSense For $500 Million

Cognex Company Profile

Cognex Corporation (NASDAQ: CGNX) develops machine vision technologies that help businesses automate inspection, identification, measurement and guidance tasks. Its systems enable manufacturing and logistics operations to analyze images and make decisions about products, components and packages.

The company’s product portfolio includes industrial cameras, vision sensors, barcode readers, three-dimensional vision systems and machine vision software. Cognex also offers artificial intelligence and deep-learning tools designed to address complex inspection and classification applications, along with engineering, implementation and support services.

Founded in 1981 by Robert J.